• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

    5/14/25 10:39:48 AM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    Personalis, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    71535D106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    71535D106


    1Names of Reporting Persons

    ARK Investment Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    7,188,197.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    7,188,197.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,188,197.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.14 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    71535D106


    1Names of Reporting Persons

    Catherine D. Wood
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    7,188,197.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    7,188,197.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    7,188,197.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.14 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Personalis, Inc.
    (b)Address of issuer's principal executive offices:

    6600 Dumbarton Circle Fremont, CA, 94555
    Item 2. 
    (a)Name of person filing:

    (i) ARK Investment Management LLC ("ARK") (ii) Catherine D. Wood
    (b)Address or principal business office or, if none, residence:

    ARK and Catherine D. Wood: 200 Central Avenue, St. Petersburg, FL 33701
    (c)Citizenship:

    (i) ARK: Delaware (ii) Catherine D. Wood: United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    71535D106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    ARK and Catherine D. Wood: 7,188,197
    (b)Percent of class:

    ARK and Catherine D. Wood: 8.14%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (i) ARK: 7,188,197 (ii) Catherine D. Wood: 0

     (ii) Shared power to vote or to direct the vote:

    (i) ARK: 0 (ii) Catherine D. Wood: 7,188,197

     (iii) Sole power to dispose or to direct the disposition of:

    (i) ARK: 7,188,197 (ii) Catherine D. Wood: 0

     (iv) Shared power to dispose or to direct the disposition of:

    (i) ARK: 0 (ii) Catherine D. Wood: 7,188,197

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    No client of ARK Investment Management LLC currently has an interest in the securities reported herein in excess of 5 percent except ARK Genomic Revolution ETF, a series of a Delaware statutory trust.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ARK Investment Management LLC
     
    Signature:/s/ Kellen Carter
    Name/Title:Kellen Carter, Chief Compliance Officer
    Date:05/14/2025
     
    Catherine D. Wood
     
    Signature:/s/ Catherine D. Wood
    Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
    Date:05/14/2025
    Get the next $PSNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    1/7/2022$27.00 → $23.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $PSNL
    SEC Filings

    See more
    • Personalis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Personalis, Inc. (0001527753) (Filer)

      5/19/25 4:10:07 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Personalis Inc.

      SCHEDULE 13G/A - Personalis, Inc. (0001527753) (Subject)

      5/14/25 10:39:48 AM ET
      $PSNL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Personalis Inc.

      10-Q - Personalis, Inc. (0001527753) (Filer)

      5/6/25 4:24:12 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      3/5/24 5:15:53 PM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates. The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection

      6/3/25 4:00:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer. "Many triple negative breast cancer patients receive neoadjuvant therapy prior to surgery as standard of care. The data from these two studies independently suggest that an ultrasensitive ctDNA assay like NeXT Personal could help these patients better un

      6/2/25 4:00:00 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

      Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection. "These studies continue to expand the clinical data for NeXT Personal into new areas, including neoadjuvant treatment in breast cancer and cervical cancer," said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis. "We continue to be driven by our mission to provide physicians and thei

      5/22/25 6:00:00 AM ET
      $PSNL
      Medical Specialities
      Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO AND COO Tachibana Aaron sold $6,390 worth of shares (1,291 units at $4.95), decreasing direct ownership by 0.78% to 165,099 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:53:11 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • SVP and Chief Legal Officer Moore Stephen Michael sold $8,291 worth of shares (1,675 units at $4.95), decreasing direct ownership by 3% to 64,200 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:51:51 PM ET
      $PSNL
      Medical Specialities
      Health Care
    • CHIEF MEDICAL OFFICER AND EVP Chen Richard sold $4,504 worth of shares (910 units at $4.95), decreasing direct ownership by 0.72% to 124,957 units (SEC Form 4)

      4 - Personalis, Inc. (0001527753) (Issuer)

      5/20/25 5:50:02 PM ET
      $PSNL
      Medical Specialities
      Health Care